The DFA Discussion, page-76

Sorry Ollie but it just isn’t so. Unblinding this late in a trial that’s already over 80 percent done isn’t blowing it up. Plenty of Phase 3 trials have done it when timing or funding forces the issue.The FDA would absolutely be involved, especially with fast track in place. They’ve allowed it before as long as the stats are handled properly and the data holds up.If the data is clean, it still counts. This isn’t trust me bro stuff, but a way to restore some shareholder value and to save the company.